Researchers at Washington University School of Medicine and the Weizmann Institute deployed engineered immune cells—using CAR‑T concepts—to clear toxic protein aggregates in Alzheimer’s disease models. The study demonstrated target engagement and reduced pathogenic protein burden in preclinical systems, suggesting a potential immunotherapy approach for neurodegeneration. The work adapts oncology cell‑therapy engineering to the CNS and highlights technical challenges around target selection, trafficking to brain tissue, and neuroinflammation control. Investigators called for further optimization and safety testing before translating the approach into human trials.